-
Mashup Score: 0
May 6, 2024 — SMT (Sahajanand Medical Technologies), a leading medical device company at the forefront of innovative patient care in the cardiovascular segment has announced a strategic partnership with HeartX, a pioneering MedTech company focused on research and development. Through this collaboration, SMT gains an innovative product line in the Congenital Heart Defect space. This collaboration not only broadens SMT’s advanced product offerings within the Congenital Heart Defect space but also marks a significant stride toward revolutionizing healthcare on a global scale. HeartX’s portfolio includes advanced products like the JOVE VB Stent for Sinus Venous ASD, JOVE Versatile ASD (VASO), Fenestrated VASO and JOVE PFO, with ongoing developments in PDA and VSD closures as well as advanced visualization systems for structural interventions. The collaboration between SMT and HeartX aims to address gaps in current medical procedures by prioritizing simplicity, efficiency, and cost reductio
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Teleflex Announces the Limited Market Release of the Wattson Temporary Pacing Guidewire - 15 hour(s) ago
May 6, 2024 — Teleflex Incorporate, a leading global provider of medical technologies, today announced that the Wattson Temporary Pacing Guidewire limited market release has commenced at Columbia University Irving Medical Center. The first cases were performed by Dr. Tamim Nazif, Director of Clinical Research, Dr. Susheel Kodali, Professor of Medicine and Director of the Structural Heart and Valve Center, and Dr. Isaac George, Surgical Director of the Heart Valve Center. Featuring a simple design to create procedural efficiencies, the Wattson Temporary Pacing Guidewire offers dual functionality, supporting both valve delivery and ventricular bipolar pacing during structural heart procedures, including transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV). The device offers a procedural alternative designed to avoid potential complications1, steps1, and costs2 associated with traditional right ventricular pacing. From its flexible distal pigtail shape to i
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent covering the use of TNX-103 (oral levosimendan), TNX-102 (subcutaneous levosimendan), TNX-101 (IV levosimendan), the active metabolites of levosimendan (OR1896 and OR18955) and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients, entitled: “LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF).” “Expanding our intellectual property estate for levosimendan is a strategic priority for Tenax. We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano, President & Chief
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0DAIC's Top 10 for April - 1 day(s) ago
Clinical trials and innovative technology took center stage during the month of April, racking up some record number views. Here is a look at what DAIC viewers were reading last month: 1. New Study Reveals 65 and Older Population Lowered Blood Pressure, Cholesterol and Weight Using Mobile Technology 2. Atlantic Health System’s Morristown Medical Center Treats First Patient in New Jersey with Edwards’ EVOQUE Tricuspid Valve Replacement 3. Shorten the Blanking Period After Atrial Fibrillation Ablation, Experts Say 4. Medtronic Launches the Avalus Ultra Valve Engineered for Ease of Use at Implant and Lifetime Patient Management 5. Incentives Prompt Increased Daily Walking in Patients at Risk for Heart Disease 6. Novel CT Exam Reduces Need for Invasive Artery Treatment 7. FDA Announces Recalls of Abbott/Thoratec Corp. Heartmate II and Heartmate 3 Left Ventricular Assist System (LVAS) Due to Long-term Buildup of biological material Causing an Obstruction 8. Around 10% of Deaths from Coronar
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
May 2, 2024 — Reprieve Cardiovascular, Inc. (‘Reprieve’), a development stage company focused on pioneering an intelligent approach to acute decompensated heart failure (ADHF) treatment, today highlighted the publication of TREAT-AHF study results in JACC: Heart Failure. Heart failure (HF) is a leading cause of hospitalization in the United States. Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss are not well described. Nearly 20 years ago, the Acute Decompensated Heart Failure National Registry (ADHERE) was published[1] and described inpatient HF treatment patterns and decongestion outcomes in a prospective national database of HF hospitalizations across 275 community and academic medical centers. As a national community-based cohort, Trajectory and Response to Emergently Administered Therapy for Acute Heart Failure (TREAT-AHF) is a contemporary registry that characterizes a diverse population of 262,673 pa
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes - 2 day(s) ago
May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. Study clinical cardiology leadership and members of the Executive Steering Committee, Dr. Carl Pepine, Professor of Medicine at the University Florida at Gainesville, and Dr. Amish Raval, Professor of Medicine at the University of Wisconsin at Madison, presented the early positive results on Tuesday, April 30, 2024 in a webcast sponsored by BioCardia. Results from the open label roll-in cohort of patients having chronic myocardial ischemia with refractory angina showed an average increase in exercise tolerance of 107 seconds and an average of 82% reduction in angina episodes at the primary six-month follow-up endpoint compared to before receiving the study treatment. All of the patients responded posi
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
May 2, 2024 — Artificial intelligence experts at Cedars-Sinai and the Smidt Heart Institute created a dataset with more than 1 million echocardiograms, or cardiac ultrasound videos, and their corresponding clinical interpretations. Using this database, they created EchoCLIP, a powerful machine learning algorithm that can “interpret” echocardiogram images and assess key findings. The design and evaluation of EchoCLIP, described in a manuscript published in the peer-reviewed journal Nature Medicine, suggest that an EchoCLIP interpretation of a patient’s echocardiogram provides clinician-level evaluations of heart function, assessment of past surgeries and devices, and may assist clinicians in identifying patients in need of treatment. The EchoCLIP foundation model also can identify the same patient across multiple videos, studies and timepoints as well as recognize clinically important changes in a patient’s heart. “To our knowledge, this is the largest model trained on echocardiograp
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
May 1, 2024 — The annual Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, and organizers report the annual meeting will bring together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine. “We are proud to offer over 80 sessions in a variety of interactive educational formats at this year’s meeting. We believe the tools, resources, and information shared at the meeting will provide the healthcare community with greater expertise to improve patient outcomes and also connect with their interventional cardiology colleagues,” said SCAI President George D. Dangas, MD, PhD, MSCAI, Icahn School of Medicine – Mt. Sinai Hospital (New York, NY). Presenting the latest cutting-edge advances in cardiovascular research, prevention, and care will be 500+ faculty, nearly 450 abstracts presenting the latest clinical data, proce
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0
May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is linked with stress and depression, putting under-65-year-olds at increased risk of dying from cardiovascular disease. The research is presented today at ESC Preventive Cardiology 2024, a scientific congress of the European Society of Cardiology (ESC).1 “Our study indicates that the air we breathe affects our mental well-being, which in turn impacts heart health,” said study lead author Dr. Shady Abohashem of Harvard Medical School, Boston, US. According to the World Health Organization, air pollution is estimated to have caused 4.2 million premature deaths worldwide in 2019.2 Mental illness has also been linked with premature death.3 This study examined whether air pollution and poor mental health are interrelated and have a joint impact on death from cardiovascular disease. The study focused on particles less than 2.5 micrometres in diameter, also referred to as fine p
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Fully-automated One-click On-site CT-FFR: a Novel Tool for Functional Evaluation for Patients with Coronary Artery Disease - 5 day(s) ago
May 1, 2024 —In this 3-stage study, 3 cohorts were used for diagnostic performance, and prognostic performance evaluation for this fully automated, one-click, on-site CT-FFR technique. This study was led by Professors Long Jiang Zhang and Guang Ming Lu (Department of Radiology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University). In cohort 1, a total of 463 patients and 600 coronary vessels with CCTA images and following invasive fractional flow reserve (FFR) results were collected for diagnostic performance and user-friendliness evaluation. CT-FFR had a strong correlation with invasive FFR both on a per-vessel basis and per-patient basis (Pearson R = 0.68, 95% CI: 0.63–0.72 and Pearson R = 0.70, 95% CI: 0.65–0.75, P 0.80) both in participants with chronic coronary syndromes and ones with acute chest pain. This is the first reported fully-automatic CT-FFR technique, and demonstrated similar diagnostic performance compared to HeartFlow and Siemens CT-FFR techniq
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
@DAICeditor #SMT (#SahajanandMedicalTechnologies) announced a strategic partnership with #HeartX, a pioneering #MedTech company focused on research and development. https://t.co/jbYkjH2mN1